Objective-Homocysteine can accelerate the senescence of endothelial progenitor cells or endothelial cells (ECs) via telomerase inactivation and length shortening. However, the underlying mechanism is unclear. Here, we investigated whether homocysteine promotes endothelial senescence by reducing the expression and activity of human telomerase reverse transcriptase (hTERT) by DNA methylation to reduce ECs telomerase activity. Approach and Results-When compared with primary human umbilical vein endothelial cells grown under standard conditions, ECs with chronic homocysteine treatment showed accelerated upregulation of p16, p21, and p53, markers of cellular senescence, during 6 to 10 passages. Interestingly, homocysteine-stimulated but not angiotensin II-stimulated ECs senescence could be reversed by hypermethylation induced by folic acid or s-adenosylmethionine supplementation. Meanwhile, homocysteine promoted the shortening of telomere length specifically related to restoration of hTERT transcriptional expression and CCCTC-binding factor binding sites with hTERT promoter hypomethylation, as detected by quantitative real-time polymerase chain reaction, Western blot, methylation-specific polymerase chain reaction, and bisulfite sequencing assay. Electrophoretic mobility shift assay and chromatin immunoprecipitation results showed that homocysteine-reduced telomere activity and homocysteine-induced EC senescence might contribute to hTERT promoter demethylation by increasing CCCTC-binding factor repression and interfering in the SP1 binding to the demethylated hTERT promoter, which might relate with reduced of DNA methyltransferase 1. Furthermore, the CCCTC-binding factor-dependent mechanism of homocysteine-reduced hTERT expression via DNA demethylation was confirmed in aortic endothelia of mice with hyperhomocysteine levels.
E xtensive cause and histology evidence demonstrated that age-related senescence and dysfunction of vascular endothelial cells (ECs) play a critical role in human atherosclerotic lesions. 1 Age-associated change in ECs includes decreasing compliance and increasing inflammation, which promote atherogenesis. 2 Shear stress-induced nitric oxide (NO) production and endothelial NO synthase (eNOS) activity were reduced in senescent human ECs. 3 Homocysteine, an independent risk factor of atherosclerosis, accelerated the onset of senescence in endothelial progenitor cells and ECs via telomerase inactivation and led to cellular dysfunction. 4, 5 Epidemiological studies have shown that elevated homocysteine levels are associated with shortened human leukocyte telomere length. 1, 6 As well, some reports have shown that inhibitors of oxidative stress could prevent homocysteine-accelerated ECs aging. 1, 5, 7, 8 However, the precise mechanisms by which homocysteine reduces telomerase activation and length remain to be determined.
Telomerase activity, which maintains telomere length and stabilizes the termini of linear chromosomes, is tightly regulated by the expression of the human telomerase reverse transcriptase (hTERT) gene. 9 Moreover, with the characterization of the genomic sequence of hTERT, demethylation with 5-aza-2-deoxycytodine (5-aza) or trichostatin A strongly reduced or even suppressed hTERT gene expression and telomerase activity and shortened telomere length in cancer cells. 10, 11 Thus, epigenetic mediation of hTERT activity may be critical to carcinogenesis. Recently, our in vivo and in vitro experiments indicated that homocysteine could affect EC dysfunction and vascular smooth muscle cell migration or proliferation via an epigenetic mechanism involving atherosclerosis-related genes. 6, 12, 13 Therefore, DNA demethylation of hTERT may be a candidate target of epigenetic regulation in homocysteine-induced EC senescence. However, homocysteine might reduce transcriptional hTERT expression by DNA hypomethylation, which reversed with homocysteine demethylation of soluble epoxide hydrolase or plateletderived growth factors and promoted their expression in our previous study. 12, 13 This contradictory hypothesis prompted us to study how DNA methylation of the hTERT promoter can lead to its activation by homocysteine in ECs.
In the core region of the 5′-hTERT promoter (−200 to +100 bp), several binding sites for activators (c-Myc, Sp1, AP2, E2F, and E-box) or repressors (p53, Mad1, MZF-2, ZRF, WT1, and CCCTC-binding factor [CTCF]) might be methylated and coregulate the expression of hTERT in human ECs. Zinn et al 14 demonstrated high expression of hTERT, despite DNA hypermethylation in several cancer cells, which contrasts with low expression with DNA hypomethylation in nontransformed cells, so some repressors might play a major role in hTERT expression and activity especially for DNA hypermethylation in some cancer cells. Similarly, hypermethylation of the CTCF repressor binding site on the hTERT promoter is necessary for reducing its expression in some cancer cells, and treatment with trichostatin A or 5-aza could allow for hTERT transcriptional expression with demethylation. [15] [16] [17] In the present study, we first showed changes in hTERT core-promoter methylation patterns and the potential role of SP1 and CTCF cross talk in hTERT gene regulation in homocysteine-induced EC senescence in vivo and in vitro. Homocysteine transcriptionally decreased hTERT expression by increasing CTCF but interfered in SP1 binding to the demethylated hTERT promoter in accelerated EC senescence. This effect could be markedly attenuated by pretreatment with folic acid (FA) or s-adenosylmethionine (SAM). Thus, epigenetic regulation of hTERT activity and EC senescence may play a critical role in homocysteine-related cardiovascular diseases.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results

Effect of SAM and FA on Homocysteine-Induced EC Senescence
To test the effects of clinically relevant doses of homocysteine on EC senescence in vitro, we exposed serial passages (P2-P10) of cultured human umbilical vein endothelial cells (HUVECs) to standard extracellular matrix in the presence or absence of 25 μmol/L homocysteine. The expression of p16, p21, and p53, markers of EC senescence, was spontaneously and persistently increased from P4 to P10 with homocysteine treatment ( Figure 1A -1D, n=4 for quantitative real-time polymerase chain reaction [qRT-PCR] and Western blot). As expected, homocysteine could accelerate EC senescence when compared with standard conditions. Interestingly, homocysteine-increased p16, p21, and p53 expressions ( Figure 1E , n=5) as well as SA-b-Gal-positive cells, apoptosis cells, and cell cycle ( Figure 1F and 1G, n=5; Figure IA and IB in the online-only Data Supplement, n=4 for each experiment), could be almost completely prevented with treatment with 50 μmol/L FA, which lowers plasma homocysteine level by increasing methionine metabolism, or partially prevented by the addition of 50 μmol/L SAM, causing DNA hypermethylation. 18, 19 However, oxidative stress can induce or accelerate the development of cellular senescence. 20 FA, an l-arginine mimic, 7 could also reverse homocysteine-decreased bioavailability of NO by upregulating eNOS expression and downregulating inducible NOS (iNOS) expression in ECs under senescence ( Figure IIA and IIB in the online-only Data Supplement, n=4 for each experiment). Therefore, FA-or SAM-induced DNA hypermethylation involved homocysteine-accelerated human endothelial senescence, independent of NO availability.
Homocysteine Demethylating the CTCF-Binding Site on the hTERT Promoter Is Associated With Telomere Attrition in ECs Under Senescence
Several reports have demonstrated that early onset senescence may be attributed to accelerated telomere attrition, probably from the generation of single-strand breaks in telomeric DNA. 21 We used a previously described telomere-length assay system 22 and found that homocysteine shortened telomere length ≈2-cell passages when compared with cells grown under standard conditions ( Figure IIIA in the online-only Data Supplement, n=4). Among 4 major essential elements of human telomerase, including the RNA subunit (hTER), catalytic subunit (hTERT), TRF2, and TP1, only hTERT expression was reduced with homocysteine stimulation at 50 μmol/L for 72 hours in ECs ( Figure IIIB in the online-only Data Supplement, n=5). Indeed, homocysteine also accelerated the reduction in hTERT mRNA and protein expression from P6 to P10 (Figure 2A , for Western blot assay, n=4; qRT-PCR, n=5). In addition, homocysteine decreased the expression of hTERT in a dose-dependent manner in P4-5 HUVECs ( Figure 2B , for Western blot assay, n=4; qRT-PCR, n=5).
Because hTERT expression is often modulated by epigenetic processes in cancer cells, 4 to understand the epigenetic regulation mechanism in the repression of hTERT in ECs with homocysteine treatment better, we performed bisulfite sequencing and methylation-specific PCR assay and examined changes in methylation of the core region of CpG sites in the hTERT promoter (from −200 to +100 bp, surrounding TSS and containing 37 CpG sites; Figure 2C, 
Homocysteine Increases CTCF and Interferes in SP1 Binding to the hTERT Promoter in ECs In Vivo
Sp1 could cooperate with the oncogene c-Myc to activate transcription of hTERT gene. 14 CTCF is a repressor of hTERT activity by demethylating its recognition sequence. 4 To understand the mechanism of cross talk of SP1 and CTCF directly regulating hTERT activity in aging HUVECs better, we first identified the putative SP1 and CTCF-binding sites in the core region of the hTERT promoter and generated their probes. EMSA (electrophoretic mobility shift assay) revealed a supershift band after the addition of anti-CTCF-specific antibody, and homocysteine or 5-aza treatment increased the binding of the hTERT promoter but with FA abolished ( Figure 3A , n=4). Moreover, demethylation by homocysteine or 5-aza also inhibited SP1 binding to the hTERT promoter but reversed by CTCF knockdown ( Figure 3B ; Figure IVA in the onlineonly Data Supplement, n=4 for each experiment). In addition, we designed ChIP (chromatin immunoprecipitation) primers for CTCF and SP1 to explore whether demethylation of CpGs could affect the ability of CTCF and SP1 to bind to the hTERT promoter with demethylation treatment. Similar to 5-aza (8 μmol/L), homocysteine (50 μmol/L) treatment for 72 hours could enhance CTCF binding (2.21-fold; P=0.043) and abolish with FA pretreatment. Furthermore, DNA demethylation by homocysteine and 5-aza could interfere in SP1 binding to the hTERT promoter (0.44-fold; P=0.031 and 0.43-fold; Figure 3C and 3D, n=4), and this effect is reversed by CTCF knockdown. In addition, we did not found the interaction of CTCF and SP1 by Co-IP assay ( Figure V in the online-only Data Supplement, n=4). Furthermore, hTERT expression and activity were decreased and EC senescence was increased with siRNA knockdown of SP1 expression, and reversed effect was observed with CTCF knockdown at basal level. However, homocysteinedecreased hTERT expression and activity and increased EC senescence could be reversed with CTCF but not SP1 knockdown ( Figure 3E -3G, n=6 for qRT-PCR, relative telomere activity, and senescence-associated β-galactosidase staining; Figure IVB in the online-only Data Supplement, n=4). Thus, SP1 might be an activator of hTERT and play a major role in its sustained expression in normal ECs when homocysteineinduced demethylation of the hTERT promoter could augment CTCF and inhibit SP1 binding to their binding sites.
Homocysteine-Decreased DNA Methyltransferase 1 Expression Involves Reduced hTERT Expression and Activity
Our previous study indicated that homocysteine treatment could specifically decrease the protein expression and activity of DNA methyltransferase 1 (DNMT1; maintaining methyltransferase activity) in ECs and was related to platelet-derived growth factor transcriptional upregulation. 6 We transfected siRNA-DNMT1 in P4 to P5 of HUVECs and found that DNMT1 knockdown ( Figure IVC in the online-only Data Supplement, n=4) could reduce the expression of hTERT, completely independent of homocysteine concentration, but induce inactivity of hTERT and EC senescence, independent of homocysteine only in part. hTERT activity was further decreased and SA-b-Gal-positive cell numbers were increased with homocysteine treatment at 200 to 500 μmol/L when DNMT1 was knocked down ( Figure 4A -4C, n=5 for qRT-PCR, relative telomere activity and senescence-associated β-galactosidase staining). Homocysteine-repressed DNMT1 expression might contribute to DNA global demethylation, including the hTERT gene, and enhance CTCF binding to the hTERT promoter, thus resulting in reduced hTERT expression and activity.
Homocysteine-Upregulation of TERT Was Confirmed in the Aortic Intima of Mice With Hyperhomocysteinemia
Previously, we established a mild and moderate hyperhomocysteinemia model (total plasma homocysteine level 27.6±4.5 and 61.5±31.4 μmol/L) with activity in the aortic endothelium in C57BL/6J mice by feeding with a diet supplemented with 2% methionine for 4 or 8 weeks (n=8 for each group). 12, 13 Real-time RT-PCR revealed 2.23±1.30-fold (P=0.043) and 4.29±1.65-fold (P=0.014) increased p16 level Figure 5A and 5B, n=8 for qRT-PCR), which indicated endothelium senescence only at 8 weeks. However, the relative telomere length in the endothelium was shortened, and mTERT protein level become decreasing as early as 4 weeks ( Figure 5C -5E, n=8 for T/S ratio, qRT-PCR, and immunohistochemistry). Meanwhile, both groups of hyperhomocysteinemia mice showed downregulation of mTERT expression and demethylation of CTCF binding sites on the mTERT promoter (from 44.1±5.5% to 21.4±4.3% at 4 weeks and from 41.3±2.3% to 8.4±5.2% at 8 weeks; Figure 5D -5G, n=8). In addition, the mRNA and protein level patterns of NOX4, a marker of oxidative stress, were similar to that of mTERT ( Figure VIA and VIB in the online-only Data Supplement, n=8). Thus, our in vivo data for epigenetic regulation of TERT by a CTCF mechanism were consistent with our in vitro observations.
Discussion
Although homocysteine-reduced telomerase activity accelerating endothelial senescence has been reported for decades, the detailed mechanism has not yet been elucidated. Here, we describe and confirm a novel hypothesis that cross talk of the transcription factors CTCF and SP1 may contribute to homocysteine-reduced DNA methylation of the hTERT promoter and expression in endothelial senescence in vitro and in vivo. Thus, maintaining telomerase activity by hypermethylating hTERT could be protective in homocysteine-related cardiovascular diseases.
Telomere-dependent vascular dysfunction has been the subject of many studies because the phenotypic changes associated with senescence were studied in vascular cell populations undergoing replicative senescence. 6 Telomere dysfunction significantly triggers oxidative stress and reduces eNOS activity; induction of TERT prevented these activities. 3, 23 Indeed, several epidemiological studies [23] [24] [25] [26] [27] [28] have shown shorter telomeres in vascular tissue in patients with coronary artery disease or early myocardial infarction than control subjects. Therefore, the degree of telomere shortening may be related to the risk of developing atherosclerotic plaque and is a predictor of mortality in patients with coronary artery disease. However, defining with certainty the role of telomeres in and the effect of telomere length on the atherosclerotic process is still difficult. 6 Experimental evidence in normal human ECs also confirmed telomerase activity, which decreases with aging of ECs because of decreased hTERT expression and leads to telomere shortening and cellular senescence. 29, 30 Conversely, telomerase overactivation extends the lifespan of ECs, 1 which suggests a close relationship between telomeres and EC senescence.
Homocysteine is considered an independent risk factor of atherosclerosis; the factor has been reported to induce telomere inactivity and shortening during accelerated EC and endothelial progenitor cell senescence. 4, 5 One possible mechanism is reduced NO activity and elevated oxidative stress by upregulating nicotinamide adenine dinudeotide phosphate oxidase. 31 Furthermore, antioxidation by selaginellin and l-arginine could protect against homocysteine-induced cell senescence in ECs. 7, 8 Antioxidants inhibit nuclear export of hTERT to the cytoplasm and delay replicative senescence of ECs. 32 Thus, Figure 3 . Homocysteine (Hcy) promoted CTCF binding but prevented SP1 binding to the human telomerase reverse transcriptase (hTERT) promoter. P4 of human umbilical vein endothelial cells (HUVECs) were treated with Hcy (50 μmol/L) or 5-aza-2-deoxycytidine (5-aza; 8 μmol/L) for 72 hours with or without presupplementation with folic acid (FA; 100 μmol/L) for 1 hour or pertransfection with si-RNA for 12 hours. A and B, EMSA (electrophoretic mobility shift assay) assay of nuclear protein incubated with biotin-labeled probes for CTCF or SP1 binding sites and anti-CTCF or SP1 antibody, then separated by 6% native PAGE. C and D, ChIP (chromatin immunoprecipitation) assays of anti-SP-1 or CTCF antibody for immunoprecipitation; Semiquantitative results of the binding of CTCF or SP-1 to the hTERT promoter. Quantitative real-time polymerase chain reaction (E), relative telomere activity (RTA; F), and senescence-associated β-galactosidase (SA-β-gal) staining (G) analyzed by SP1 or CTCF knockdown on transfection with 40-nmol/L siRNA targeting SP1 and CTCF or scramble siRNA control (si-Ctrl) for 12 hours, and with or without Hcy treatment for 72 hours. β-Actin was an internal control. Data are mean±SD and analyzed by Student t test. *P<0.05 and #P<0.05 vs si-Ctrl without Hcy treatment, respectively. For EMSA and ChIP assays, n=4; qRT-PCR, RTA, and SA-β-gal staining, n=6.
NO reduction by oxidative stress may be the critical step in homocysteine-induced telomerase inactivity.
In the current study, for markers of EC senescence, levels of TIMP4 (tissue inhibitor of metalloproteinases 4) and NOX4 (NADPH oxidase 4), 2 markers of oxidative stress, were increased in a passage-dependent manner and were significantly enhanced by homocysteine treatment (data not shown). Preincubation with a repressor of oxidative stress (l-arginine), by increasing NO synthesis, could markedly abolish the homocysteine-induced level of p16 or p21 and the ratio of senescence-associated β-galactosidase-positive cells but not the expression of hTERT. Interestingly, homocysteine but not angiotensin II-induced EC senescence and reduced hTERT level could be attenuated by DNA hypermethylation with treatment with FA or SAM. Moreover, inhibition of DNA methylation by 5-aza alone could mimic the homocysteine effect on hTERT expression and demethylation. Therefore, homocysteine might downregulate hTERT level independently to induce telomerase inactivity, which differs from oxidative stress and NO reduction. Thus, we found another novel mechanism of homocysteine inactivating telomerase activity by directly downregulating hTERT expression with DNA demethylation during endothelial aging. Previously, we and others suggested that homocysteine reduced the expression and activity of DNMT1 and further demethylated promoters of atherosclerosis-related genes and enhanced their expression. 13, 33 Thus, our current report clarifies that hTERT is a novel target gene in homocysteine-induced endothelial dysfunction by an epigenetic mechanism, just as hTERT is a candidate target gene via DNA hypomethylation in various carcinogenesis paths. 4 Similar to previous studies, 14 we found that the core region of the hTERT promoter showed only low-density methylation (16.9%) in normal ECs and mainly focused on the SP1 (62.5%) and CTCF-binding sites (66.7%) in the core region. Importantly, both sites showed a decreasing methylation pattern by inhibiting histone deacetylase by trichostatin A (data not shown) or DNA demethylation by homocysteine or 5-aza, which facilitated CTCF but interfered SP1 binding to the hTERT promoter but did not alter their expression. Surprisingly, different from Choi et al 11 and Meeran et al, 17 our ChIP analysis confirmed that homocysteine-or 5-azainduced demethylation promoted CTCF but prevented SP1 combining to the hTERT promoter. SP1 binding to homocysteine-induced unmethylated CpGs on the promoter of hTERT might be an activator for hTERT expression in normal ECs because siRNA knockdown of SP1 repressed hTERT expression and activity in ECs without but not with homocysteine treatment. However, siRNA knockdown of CTCF could upregulate hTERT expression whether SP1 was deleted, which suggests that homocysteine enhanced CTCF (repressor) but interfered in SP1 (activator) binding to the hTERT promoter and coordinately contributed to hTERT downregulation. Although the inhibitory effect of CTCF recruitment on SP1 binding to the homocysteine-demthylated hTERT promoter is not clear, CTCF might affect the interaction of SP1 and p300 or c-Myc in intrinsic histone acetyltransferase activity, 4 which explains the cross talk of CTCF and SP1 contributing to homocysteine-repressed hTERT activity in ECs. In our previous study, 13 we found that treatment with a moderate concentration of homocysteine for long-term stimulation could inhibit the activity and expression of DNMT1 in HUVECs. DNMT1 knockdown could reduce the expression and activity of hTERT completely independent of homocysteine but induce EC senescence independent of homocysteine only in part. Together with other data, 34, 35 our data support that hTERT transcriptional expression can be controlled by DNMT1 in ECs and other specific cancer cells; decreased DNMT1-induced demethylation focuses on fully methylated CpGs of the CTCF-binding site in cancer cells and on partially methylated CpGs in ECs.
According to Horikawa et al 36 and Ritz et al, 32 humans and mice might share a similar pattern of TERT expression. Thus, we examined homocysteine-reduced hTERT activity via DNA demethylation in an hyperhomocysteinemia mouse model. Indeed, cellular senescence, shortened telomere length, and mTERT protein reduction in the intima were found only with moderate hyperhomocysteinemia (8 weeks). Although we detected elevated mTERT mRNA levels and hypomethylation of CTCF-binding sites on mTERT in the mouse aortic intima with short-term (4 weeks) mild hyperhomocysteinemia treatment, which indicates that DNA demethylation is an early event in hyperhomocysteinemia, it was not sufficient to cause EC senescence. Hyperhomocysteinemia-activated oxidative stress might play a crucial role combined with hTERT reduction in EC senescence. 37 The limitations of our study is that we performed no atherosclerotic lesion experiments in vivo to identify whether homocysteine-induced hTERT repression and shortened telomere length is a cause or consequence in atherosclerosis. However, homocysteine affecting the cross talk of CTCF and SP1 in demethylating the hTERT promoter and reducing hTERT expression is a rapid and critical step for telomere dynamics in circulating cells, cultured ECs, and aortic intima. These areas are affected directly by homocysteine at the early stage of atherosclerotic lesion development, and combined with oxidative stress, cocontribute to telomerase inactivation, thus further leading to EC senescence in homocysteine-related cardiovascular diseases.
In conclusion, our in vivo and in vitro findings show a novel mechanism of CTCF and SP1 cross talk coordinately contributing to homocysteine-induced DNA demethylation on the hTERT promoter and restoring its expression, for accelerated EC telomerase inactivation and senescence. In addition, our study also supports that hTERT mRNA expression or methylation ratio is an early risk event in homocysteineinduced cardiovascular disease. 
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